TriSalus Life Sciences (TLSI) Q2 FY26 earnings call

TriSalus delivered a strong second quarter, driven by commercial expansion and progress in clinical evidence generation for its TriNav system. The company secured a significant G-code from CMS, expanding reimbursement into office-based labs, which is expected to accelerate adoption across liver and non-liver indications. While investments in commercial infrastructure led to increased losses, management reiterated full-year revenue guidance, expressing confidence in future growth and disciplined cost control.